良性前列腺增生合并前列腺炎患者的临床特点分析

目的 探讨合并前列腺炎的良性前列腺增生(BPH)患者的临床特点. 方法 BPH患者100例.按是否合并前列腺炎分为单纯组(34例)和合并组(66例).比较2组患者年龄、前列腺体积、PSA与前列腺特异性抗原密度(PSAD)、国际前列腺症状评分(IPSS)的差异,同时分析B超检查对BPH合并前列腺炎的检出情况. 结果单纯组患者年龄为(66.5±6.4)、合并组为(69.9±7.2)岁;单纯组平均前列腺体积为(47.5±26.7)、合并组为(71.4±39.3)ml.单纯组患者PSA和PS-AD中位数分别为3.40和0.08 ng/ml,合并组分别为8.07和0.12 ng/ml;平均IPSS分别为19.9和22.2.2组患者平均年龄、前列腺体积、PSA与PSAD值及IPSS评分比较,差异均有统计学意义(P<0.05).合并前列腺炎患者前列腺体积与炎症浸润程度及腺体破坏程度具有相关性(r分别为0.29,0.25,P<0.01).PSA与前列腺炎浸润分级和破坏分级均具有相关性(r分别为0.319和0.214,P值均<0.05).PSAD与浸润分级具有相关性(r=0.212,P<0.05).B超诊断BPH合并前列腺炎的敏感性为21.2%,特异性82.4%. 结论 BPH患者多伴前列腺炎,且以慢性炎性细胞浸润为主;合并前列腺炎的患者临床检测指标明显高于单纯BPH患者.B超对BPH合并前列腺炎的检出能力不令人满意.     

单纯良性前列腺增生与合并慢性前列腺炎患者临床特点分析

目的:探讨单纯良性前列腺增生(BPH)与合并慢性前列腺炎(CP)患者的临床特点及其意义。方法:回顾性分析2011年10月~2013年06月我院泌尿外科行经尿道前列腺等离子电切术(TURP)治疗BPH的患者236例,按照病理诊断分为单纯BPH(35例)和合并CP(201例)两组,采用SPSS 17.0软件进行统计学分析,比较两组患者在年龄、前列腺体积、最大尿流率(Qmax)、剩余尿量(RUV)、国际前列腺症状评分(IPSS)(术前及术后3个月)、生活质量评分(QOL)、是否发生急性尿潴留(AUR)、前列腺特异性抗原(PSA)、前列腺特异性抗原密度(PSAD)等指标上是否存在差异。结果:合并CP组患者在前列腺体积、RUV、IPSS、QOL、AUR发生率等方面指标高于单纯BPH组患者,Qmax低于单纯BPH组,差异有统计学意义。而在年龄及PSA、PSAD等方面指标差异无统计学意义。手术治疗后3个月两组IPSS评分均较术前明显降低,且合并CP组较单纯组评分高,差异均有统计学意义。结论:CP可能是BPH临床进展的重要因素之一,同时也可能是导致BPH患者下尿路症状(LUTS)的重要原因之一。     

单纯前列腺增生与合并前列腺炎患者临床特点分析

目的 探讨单纯前列腺增生(BPH)与合并慢性前列腺炎(CP)患者在临床特点上的差异.方法 回顾性分析2005年至2010年于我院行经尿道前列腺电切术(TURP)术治疗的BPH患者,按照是否合并CP,分为单纯BPH组和合并CP组两组,采用SPSS17.0软件进行统计学分析,比较两组患者在年龄、临床症状、前列腺体积、国际前列腺症状评分(IPSS)、PSA等指标上是否存在差异.结果 288例BPH患者中合并CP有63例.单纯BPH患者多因尿频、排尿困难入院,而合并有CP的BPH患者中有79.6%因疼痛或终末尿滴沥入院;虽然合并CP患者较单纯BPH患者发病年龄更高、前列腺体积更大、PSA更高,但差异无统计学意义;合并CP患者较单纯BPH患者IPSS更高,差异有统计学意义.结论 有无疼痛或终末尿滴沥及IPSS高低是临床鉴别单纯BPH患者与合并CP的BPH患者的重要指标;在IPSS评分大于25分时应警惕前列腺炎的存在.     

组织学改变在BPH并发急性尿潴留患者中的作用分析

目的:探讨前列腺梗死、前列腺组织学炎症、前列腺增生类型在良性前列腺增生(BPH)并发急性尿潴留(AUR)中的关系。方法:回顾性分析我院初诊BPH合并AUR与无AUR患者共102例,其中AUR组49例,无AUR组53例。比较两组之间前列腺梗死、前列腺组织学炎症、前列腺增生类型发生率。同时比较两组间年龄、国际前列腺症状评分(IPSS)、前列腺特异性抗原(PSA)、前列腺总体积(PV)。结果:AUR组血PSA较无AUR组明显升高[(8.2±4.6)μg/L vs(4.3±5.5)μg/L,P<0.05),两组患者年龄、IPSS、PV比较差异无统计学意义(P均>0.05)。前列腺增生类型与AUR无相关性(P>0.05),前列腺梗死和前列腺组织学炎症可增加BPH患者AUR发生机率,存在前列腺梗死的BPH患者发生AUR的概率是无前列腺梗死者的5.620倍(P<0.05),存在前列腺组织学炎症的BPH患者发生AUR的概率是无炎症者的2.362倍(P<0.05)。结论:前列腺梗死和前列腺组织学炎症可能是BPH患者发生AUR的危险因素。     

前列腺增生症伴或不伴组织学前列腺炎患者临床特点分析

目的 探讨组织学前列腺炎(histological prostatitis,HP)与良性前列腺增生(BPH)患者临床特点的相关性.方法 BPH患者1 68例,根据伴或不伴HP分为HP组(n=96)和非HP组(n=72).比较分析两组患者年龄、前列腺体积、PSA、PSAD、国际前列腺症状评分(IPPS)、术前合并尿路感染和急性尿潴留情况的差异.结果 非HP组和HP组平均年龄、前列腺体积、PSA、PSAD、IPPS、术前合并尿路感染和急性尿潴留情况分别为(68.9±6.9)与(71.7±7.1)岁、(60.1±31.5)与(70.5±30.7) ml、(5.82±4.4)与(7.59±5.9)ng/ml、(0.105±0.084)与(0.111±0.079)、(17.2±3.4)与(20.9±3.7)、27.8％ (20/72)与30.2％ (29/96)、25.0％ (18/72)与40.6％ (39/96).两组患者年龄、前列腺体积、PSA、IPPS、术前合并急性尿潴留情况比较,差异均有统计学意义.PSAD和术前合并尿路感染情况比较,两组差异无统计学意义.结论 HP的发生与尿路感染无关,但与患者年龄、前列腺体积相关；合并HP会加重BPH患者尿路症状,并增加出现急性尿潴留的风险；对BPH合并HP患者血清PSAD较PSA更具特异性,并增加出现急性尿潴留的风险.     

前列腺增生合并组织学前列腺炎患者的临床特征及术后并发症分析杜国伟1,熊晶1,2,陈赵1,陈洪波3,却晖4,郑江5,姚启盛6,耿杰7,贺大林8,王行环1,

目的 分析合并组织学前列腺炎的良性前列腺增生(BPH)患者的临床特征及经尿道前列腺等离子双极电切术后并发症。方法 选取多中心2016年12月至2018年8月接受经尿道前列腺等离子双极电切手术的638例病例进行回顾性分析。根据病检结果分为单纯性前列腺增生组(增生组)和前列腺增生合并组织学前列腺炎组(增生伴炎症组)。比较两组的年龄、病检结果、体质指数、前列腺体积、最大尿流率(Qmax)、残余尿量(PVR)、血清前列腺特异性抗原(PSA)、国际前列腺症状评分(IPSS)、生活质量指数评分(QOL)、术后并发症,随访术后3个月患者的IPSS及QOL。结果 638例BPH患者中,合并组织学前列腺炎218例,检出率为34.2%,其中患者术前最大尿流率、IPSS评分、IPSS-V、IPSS-S、QOL评分两组间差异有统计学意义(P0.05);年龄、体质指数、前列腺体积、残余尿量、总前列腺特异抗原(T-PSA)、游离前列腺特异抗原(F-PSA)、游离前列腺特异抗原与总前列腺特异抗原比值(F-PSA/T-PSA)两组间比较无统计学差异(P0.05);两组术后IPSS、IPSS-S、IPSS-V、QOL评分均较术前显著下降(P0.001);术后IPSS-S增生伴炎症组较增生组高,说明增生伴炎症组储尿期症状改善较差(P=0.021);另外,术后并发症发生率增生组为8.3%,增生伴炎症组为13.8%,差异有统计学意义(χ2=4.621,P0.05),其中增生伴炎症组术后膀胱痉挛发生率5.05%显著高于增生组0.95%(χ2=10.475,P=0.001)。结论 合并组织学前列腺炎会加重下尿路症状,对BPH疾病的进展具有促进作用,术后储尿期症状改善没有单纯性前列腺增生患者明显,合并组织学前列腺炎会增加术后并发症的发生,因此在防治BPH的过程中,应注意前列腺炎症性改变,防止术后并发症的发生。     

保列治治疗合并慢性前列腺炎的良性前列腺增生症疗效观察

目的 观察保列治治疗合并慢性前列腺炎的良性前列腺增生症的临床疗效。方法 选择经临床确诊的合并慢性前列腺炎的良性前列腺增生症患者40例,口服保列治5 mg,1次/d,共3个月,分别于治疗前,治疗3个月后行国际前列腺症状评分(IPSS)、尿流率、残余尿量、前列腺体积及前列腺液常规等指标测定。结果 用药3个月后IPSS平均降低31.6％,最大尿流率平均升高38.3％,残余尿量平均减少38.6％。前列腺体积平均缩小18.1％。前列腺液白细胞计数平均减少39.8％。前列腺液检查好转率50％。前列腺体积≥40 mL组及<40 mL组的前列腺液检查好转率分别为66.7％及31.6％,两者比较P<0.05。结论 保列治治疗合并慢性前列腺炎的良性前列腺增生症,对慢性前列腺炎及良性前列腺增生症均效果良好。对慢性前列腺炎伴前列腺体积较大者效果尤佳。     

前列腺增生合并前列腺炎的临床研究

目的探讨前列腺增生(BPH)合并前列腺炎(CP)的临床特点及其相互关系。方法对我科于2000年1月～2009年12月收治的287例BPH合CP患者进行回顾性分析。根据有无合并CP,将所有患者分为CP组(124例)和非CP组(163例),比较两组患者年龄、EPS白细胞数量、前列腺特异性抗原(PSA)、前列腺体积、国际前列腺症状评分(IPSS)及生活质量评分(QOL)的差异。然而根据有无接受抗CP治疗,进一步将CP组患者分为治疗组(73例)和对照组(51例),比较两组治疗前后IPSS和QOL评分的变化。结果与非CP组相比,CP组患者发病年龄更迟、血清PSA值更高、前列腺体积更大、IPSS及QOL评分更高(均P0.05),但EPS白细胞计数两组比较,差异无统计学意义(P0.05)。治疗组治疗后,IPSS及QOL评分明显下降(P0.05),而对照组治疗后IPSS及QOL评分未明显改善(P0.05)。结论 BPH常合并CP;与单纯BPH相比,BPH合并CP具有发病年龄迟、血清PSA更高、临床症状更为严重的特点;在常规BPH治疗的同时予以抗CP治疗,可取得更为显著的疗效。     

良性前列腺增生患者合并前列腺炎与膀胱出口梗阻的相关性研究

目的 探讨BPH患者合并前列腺炎与膀胱出口梗阻(BOO)的相关性.方法 选取2008年1月至2012年1月BPH患者300例.年龄47 ～ 93岁,平均69岁.按是否合并前列腺炎分为单纯BPH组136例,PSA(4.9±8.3) μg/L,前列腺体积(41.4±18.1)ml,IPSS评分(21.9 ±7.0)分;合并前列腺炎组164例,PSA(7.0±8.5) μg/L,前列腺体积(48.7±20.7) ml,IPSS评分(27.5±5.1)分.比较两组尿动力学检查梗阻指标的差异.结果 单纯BPH组与合并前列腺炎组的Qmax分别为(8.8±4.8)ml/s和(6.3±3.7) ml/s,差异有统计学意义(P＜0.05);最大尿流率时逼尿肌压力分别为(96.7±33.0)cm H2O(1 cm H2O=0.098 kPa)和(113.2 ±39.8)cmH2O,差异有统计学意义(P＜0.05);Abrams-Griffiths(A-G)指数分别为77.7 ±31.9和93.9 ±39.6,差异有统计学意义(P＜0.05);Schafer分级值分别为3.3±1.5和4.4±1.2,差异有统计学意义(P＜0.05).Logistic回归分析显示前列腺炎症(OR=2.66,P=0.002)、前列腺体积(OR=1.37,P=0.000)、Qmax(OR =0.72,P=0.000)与Schafer分级有相关性.结论 前列腺炎会加重BPH患者BOO程度.     

血清PSA、游离PSA与良性前列腺增生临床的相关性研究

目的分析血清前列腺特异性抗原(PSA)及游离前列腺特异性抗原(fPSA)与良性前列腺增生(BPH)临床的相关性。方法应用化学发光微粒子免疫分析法(CMIA)对BPH患者血清PSA、fPSA进行检测。结果入选的40例患者病理均为BPH。PSA>4ng/ml者,术后随访1～3个月,平均2.5个月,PSA值均降至0.02ng/ml以下,可除外前列腺癌(PCa)病例。PSA<4ng/ml者16例(40%),4～10ng/ml者14例(35%),>10ng/ml者10例(25%);fPSA>0.934ng/ml者22例(55%)。血清PSA、fPSA水平与前列腺总体积(PV)、前列腺移行区体积(TZV)、年龄及国际前列腺症状评分(IPSS)呈正相关。结论本组血清fPSA与PV、TZV、年龄、IPSS评分有更强相关性。BPH患者血清PSA、fPSA水平升高的相关因素与前列腺总体积及移行区增大、高龄及高IPSS评分有关。     

不同程度前列腺组织学炎症对良性前列腺增生临床进展性的影响

目的 探讨不同程度前列腺组织学炎症对良性前列腺增生(BPH)临床进展性的影响.方法 经尿道前列腺等离子电切术(PKRP)的83例BPH患者临床资料,根据病理结果伴炎症分为轻度炎症组和中重度炎症组,应用统计软件进行分析,比较各组之间临床进展性的差异.结果 83例患者中,63例伴有组织学炎症,检出率为75.90％,其中轻度炎症为44例(69.84％),中度16例(25.39％),重度3例(4.76％),轻度炎症组与中重度炎症组相比国际前列腺症状评分(IPSS)、前列腺体积(PV)、急性尿潴留(AUR)的发生率均明显增高(P＜0.05);最大尿流量(Qmax)明显降低(P=0.002);炎症程度越重,高梗阻分级所占的比例则越高(P=0.034)o结论 前列腺组织学炎症可增大PV,加重膀胱出血梗阻(BOO)程度,降低Qmax,加重患者下尿路(LUTS)症状,增加AUR等并发症的发生率,是BPH临床进展的重要因素之一.     

血清前列腺特异性抗原检测预测良性前列腺增生并发急性尿潴留的应用价值

目的 探讨血清前列腺特异性抗原(PSA)检测预测良性前列腺增生(BPH)并发急性尿潴留(AUR)的应用价值,为BPH并发AUR的临床治疗和预后提供参考.方法 选取本院2013年1月～ 2014年12月收治住院治疗的289例BPH患者的临床资料,其中并发AUR者183例(AUR组),未并发AUR者106例(非AUR组).比较两组患者总血清前列腺特异性抗原(tPSA)、tPSA/年龄、前列腺体积(PV)及PSA密度(PSAD)水平的差异;分析两组患者不同tP-SA、PV及PSAD水平的分布率.结果 AUR组tPSA、tPSA/年龄、PV及PSAD均大于非AUR组,两组比较差异均有显著性统计学意义(P＜0.01).Sperman's相关性分析表明,tPSA、tP-SA/年龄及PSAD间存在正相关性(r=0.921,P＜0.05);tPSA与PV间呈正相关性(r=0.920,P ＜0.05).随着tPSA、PV及PSAD水平的逐渐增加,AUR的发生率逐渐升高.结论 PSA的检测可作为BPH并发AUR的预测指标,值得临床推广应用.临床检测中应结合tPSA/年龄、PV及PSAD等结果综合考虑.     

Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial

What’s known on the subject? and What does the study add? Treatment of benign prostatic hyperplasia (BPH) centres on two drug classes, 5α‐reductase inhibitors and α‐blockers. The 4‐year Combination of Avodart® and Tamsulosin (CombAT) study investigated whether the combination of dutasteride and tamsulosin was more effective than either monotherapy in reducing the relative risk of AUR, BPH‐related surgery, and BPH clinical progression in men with moderate‐to‐severe LUTS who were at increased risk of disease progression. Data from the 2‐ and 4‐year, pre‐planned primary and secondary endpoint analyses for the CombAT study have been reported previously. This study reports the outcomes of post hoc analyses of the influence of baseline parameters on the incidence of AUR, BPH‐related surgery, and overall clinical progression in patients treated with tamsulosin, dutasteride, or combination therapy with both agents.

OBJECTIVE

? To investigate the influence of baseline variables on the 4‐year incidence of acute urinary retention (AUR), benign prostatic hyperplasia (BPH)‐related surgery and overall clinical progression in men treated with tamsulosin, dutasteride, or a combination of both.

PATIENTS AND METHODS

? The 4‐year Combination of Avodart® and Tamsulosin (CombAT) study was a multicenter, randomized, double‐blind, parallel‐group study of clinical outcomes in men aged ≥50 years with symptomatic (International Prostate Symptom Score [IPSS]≥12) BPH, with prostate‐specific antigen (PSA) levels of ≥1.5 ng/mL and ≤10 ng/mL, and a prostate volume (PV) of ≥30 mL. ? Eligible patients received tamsulosin 0.4 mg, dutasteride 0.5 mg, or a combination of both. ? The primary endpoint was time to first AUR or BPH‐related surgery. Secondary endpoints included clinical progression of BPH and symptoms. Posthoc analyses of the influence of baseline variables (including age, IPSS health‐related quality of life [HRQL], PV, PSA, IPSS, peak urinary flow rate [Q_max] and body‐mass index [BMI]) on the incidence of AUR or BPH‐related surgery, clinical progression of BPH, and symptoms were performed.

RESULTS

? There were 4844 men in the intent‐to‐treat population. Overall baseline characteristics were similar across all patient groups. ? Regardless of baseline subgroup, the incidence of AUR or BPH‐related surgery was higher in men treated with tamsulosin than in those treated with dutasteride or combined therapy. ? Combined therapy was statistically better than tamsulosin in reducing the risk of AUR or BPH‐related surgery in subgroups of baseline PV > 42.0 mL, in all subgroups of baseline PSA level, and all other baseline subgroups (P≤ 0.001). ? Across treatment groups, the incidence of clinical progression was highest in men with a baseline IPSS of <20 or IPSS HRQL score of <4. The incidence of clinical progression was also higher in men receiving tamsulosin than dutasteride or combined therapy in all baseline subgroups, except for men with a baseline PV of <40 mL. Combined therapy reduced the relative risk (RR) of clinical progression compared with tamsulosin across all baseline subgroups and compared with dutasteride across most baseline subgroups. ? Symptom deterioration was the most common progression event in each treatment group regardless of baseline subgroup, except in those men with an IPSS of ≥20 at baseline. Combined therapy reduced the RR of symptom deterioration compared with tamsulosin across all but one baseline subgroup (the reduction was not significant for men with a baseline PV of <40 mL) and compared with dutasteride in most subgroups.

CONCLUSIONS

? Men with a baseline PV of ≥40 mL and any baseline PSA level of ≥1.5 ng/mL had greater reductions in the RR of AUR or BPH‐related surgery and greater reductions in the RR of clinical progression and symptom deterioration on combined therapy or dutasteride monotherapy than on tamsulosin monotherapy. ? These analyses support the long‐term use of combined therapy with dutasteride plus tamsulosin in men with moderate‐to‐severe BPH symptoms and a slightly enlarged prostate.     

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes

OBJECTIVES: To assess the utility of voiding and filling symptom subscores in predicting features of benign prostatic hyperplasia (BPH) progression, including acute urinary retention (AUR) and prostate surgery. METHODS: The Proscar Long-term Efficacy and Safety Study (PLESS) was a 4-year study designed to evaluate the effects of finasteride versus placebo in men with lower urinary tract symptoms (LUTS), clinical evidence of BPH, and no evidence of prostate cancer. A self-administered questionnaire was employed to quantify LUTS at baseline. Receiver operating characteristics (ROC) curves were used to assess baseline characteristics from patients treated with placebo as predictors of outcomes. The characteristics assessed included the overall symptom score (Quasi-AUA SI), separate voiding and filling subscores, prostate volume (PV) and serum prostate-specific antigen (PSA) levels. RESULTS: PV and PSA were superior to the symptom scores at predicting episodes of spontaneous AUR and all types of AUR. The Quasi-AUA SI and the filling and voiding subscores were effective at predicting progression to surgery; however, PSA was more effective at predicting this outcome. To better evaluate symptoms as predictors of surgery, patients who experienced a preceding episode of AUR were excluded from the surgery analysis. In the absence of preceding AUR, the best predictors of future surgery were the Quasi-AUA SI and the filling subscore. CONCLUSIONS: Among men with LUTS, clinical BPH and no history of AUR, the overall symptom score and storage subscore are useful parameters to aid clinicians in identifying patients at risk for future prostate surgery. PV and PSA were the best predictors of AUR, while PSA was the best predictor of prostate surgery (for all indications).     

七叶皂苷片促进合并组织学炎症的前列腺增生患者术后下尿路症状的改善

目的探讨将七叶皂苷片应用于合并前列腺组织学炎症的前列腺增生（BPH）患者,观察其对经尿道前列腺电切术（TURP）后早期下尿路症状（LUTS）的改善作用。 方法2015年11月至2018年5月,我院116例合并前列腺组织学炎症的BPH患者,随机分为治疗组（n=58）和对照组（n=58）,均行TURP。治疗组在对照组基础上,从手术后第3天起开始口服七叶皂苷片2片/次,2次/d,直至拔导尿管后4周。记录两组患者术前、拔管后第7天和拔管后第28天的国际前列腺症状评分（IPSS）和生活质量（QOL）评分,并记录两组急性尿潴留（AUR）和急迫性尿失禁（UUI）发生的例数。 结果两组患者术后IPSS和QOL评分均较术前有明显下降,但治疗组较对照组的IPSS和QOL评分下降幅度更大,差异有统计学意义（P<0.05）,治疗组发生UUI的例数明显少于对照组,差异有统计学意义（P<0.05）,而两组发生AUR的例数差异无统计学意义。 结论七叶皂苷片可以促进合并前列腺组织学炎症的BPH患者TURP术后早期LUTS的改善。     

Relation between acute urinary retention, chronic prostatic inflammation and accompanying elevated prostate-specific antigen

OBJECTIVE: To determine if there is a relationship between acute urinary retention (AUR), the prostate-specific antigen (PSA) level and chronic inflammation of the prostate. We therefore studied patients with benign prostatic obstruction (BPO) with (n = 64) or without (n = 168) acute urinary retention (AUR) who underwent transurethral resection of the prostate (TURP) in a retrospective case control study. MATERIAL AND METHODS: Between 2001 and 2004, a total of 232 patients underwent TURP due to BPO with or without AUR. The mean values of age, prostate volume, weight of resected prostate and PSA level and the histopathologic results of patients with and without AUR were compared. Chi(2) analysis was used to examine the relationship between prostatic inflammation and AUR. The contribution of each variable to AUR was assessed by means of multiple linear regression. RESULTS: A total of 64 patients (28%) were operated on for AUR due to BPO. There were no statistical differences between patients with or without AUR with respect to the mean values of PSA, percent free PSA, prostate size or weight of the resected prostate tissue. Elevated PSA values (>or=4.0 ng/ml) were detected in 64% and 38% of the patients in the AUR and non-AUR groups, respectively (p = 0.01). Histopathological re-evaluation demonstrated that chronic prostatic inflammation was present in 56% and 37% of the specimens in the AUR and non-AUR groups, respectively (p = 0.014). In the AUR group, the mean PSA level was significantly higher in patients with than without prostatic inflammation (7.75+/-5.26 vs 5.07+/-3.21 ng/ml; p = 0.022). The odds ratio of AUR for patients with chronic prostatic inflammation and elevated PSA was determined as 4.14 (95% CI 1.65-10.41). Multiple linear regression revealed that prostatic inflammation made a significant contribution to AUR. CONCLUSIONS: Chronic prostatic inflammation may be histopathological evidence of both elevated PSA level and AUR; hence it may play a role in the pathophysiology of AUR.     

良性前列腺增生症发生急性尿潴留的相关因素分析

目的:应用临床常用指标,探讨BPH发生急性尿潴留(AUR)的相关因素。方法:回顾分析538例BPH患者相关资料。分为曾发生AUR(A组)260例,从未发生AUR(B组)278例。分别比较两组间在年龄(AGE)、前列腺总体积(PV)、前列腺移行区体积(TZV)、移行区指数(TZI)和前列腺特异抗原(PSA)、游离前列腺特异抗原(F-PSA)、游离与总前列腺特异抗原比值(F/T-PSA)等指标上的差异性。结果:A组平均PV、TZV和PSA值皆明显高于B组,上述3个指标在两两组间差异有统计学意义,且PSA与PV、TZV均有正相关性。结论:PV、TZV及PSA可作为预测BPH发生AUR的良好指标。     

前列腺增生急性尿潴留TWOC失败的因素分析

目的分析前列腺增生引起的急性尿潴留患者进行留置导尿后再予以试行拔除尿管(TWOC)后患者再次发生尿潴留的危险因素。方法回顾性分析2017年4月至2019年4月在自贡市第一人民医院治疗的前列腺增生并发第一次急性尿潴留的65例患者的临床资料,65例患者既往均接受了在留置尿管后口服0.4mg/d盐酸坦索罗辛并在第3天进行试行拔管的处理,拔管后患者再次出现尿潴留视为TWOC失败,单因素及多因素Logistic回归分析患者年龄、前列腺体积、膀胱内前列腺突出度(IPP)、国际前列腺症状评分(IPSS)等相关参数与TWOC失败的相关性。结果 TWOC成功组23例(35.4%),TWOC失败组42例(64.6%),单因素分析结果显示TWOC成功组与失败组比较前列腺体积(P=0.030)、IPSS(P<0.001)、IPP(P=0.002)存在明显统计学差异。多因素Logistic回归分析得出患者IPSS(OR=2.462,95%CI:1.216~4.985,P=0.012),IPP(OR=2.606,95%CI:1.224~5.545,P=0.013)是TWOC失败的独立危险因素。结论患者IPP、IPSS评分是预测TWOC失败的重要指标。     

良性前列腺增生症急性尿潴留的临床预测

目的 应用临床常用指标，预测良性前列腺增生(BPH)发生急性尿潴留(AUR)的几率。方法 回顾78名BPH患者病史，分为曾发生AUR(A组)28例，从未发生AUR(B组)50例。分别比较两组间在前列腺总体积(PV)、前列腺移行区体积(TZV)、移行区指数(TZI)和前列腺特异抗原(PSA)、游离前列腺特异抗原(F-PSA)、游离与总前列腺特异抗原比值(F/T-PSA)等指标上的差异性，寻找其中能用于预测AUR的临床指标。应用ROC曲线即受试者工作特性曲线，确定相关指标预测AUR的分界值。结果 A组平均PV、TZV和PSA值皆明显高于B组，上述3个指标在A、B两组间存在显著性差异。而A、B两组在年龄、TZI、F-PSA、F/T-PSA上都无显著性差异。在预测AUR方面PSA可能比前列腺体积指标更具临床价值。结论 可通过PV、TZV及PSA来预测BPH中AUR的发生。根据不同临床需要确定预测AUR的临界值，有利于及早对BPH高危人群进行监控和治疗干 预。